Repercussions of occult malignancy - An etiologic basis for rheumatic disease

Medical Hypotheses

Volumn 80, Issue 4, 2013, Pages 447-451

  Johnson, Andrew Kelly ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CANCER ANTIBODY; CYCLINE; HLA B8 ANTIGEN; TUMOR ANTIGEN;

ADENOCARCINOMA; ALLERGIC ENCEPHALITIS; ANTIGENICITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER CELL; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CROSS REACTION; DERMATOMYOSITIS; EATON LAMBERT SYNDROME; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INFECTION; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MELANOMA; MULTIPLE SCLEROSIS; NEOPLASM; OCCULT CANCER; PARANEOPLASTIC SYNDROME; RHEUMATIC DISEASE; SMOKING; SQUAMOUS CELL CARCINOMA; TUMOR IMMUNITY; VITILIGO;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; NEOPLASMS, UNKNOWN PRIMARY; PARANEOPLASTIC SYNDROMES; RHEUMATIC DISEASES;

EID: 84875384536     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.12.038     Document Type: Article

References (67)

1. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Geneeskd 1909, 5:273-290.
2. ThomasL L. Cellular and humoral aspects of the hypersensitive states 1959, 529-532. Hoeber-Harper, New York. H.S. Lawrence (Ed.).
3. Burnet F.M. Cancer-a biological approach. Brit Med J 1957, 1:841-847.
4. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res 1970, 1-27.
5. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
6. Naschitz J.E. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol 2001, 13(1):62-66.
7. Zhang J.-Y., Casiano C A., Peng X.-X., Koziol J.H., Chan E.K.L., Tan E.M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 2003, 12:136-143.
8. Blumberg B.S. Hepatitis B virus, the vaccine and the control of primary cancer of the liver. Proc Natl Acad Sci USA 1997, 94:7121-7125.
9. Berk P.D., Okuda K., Wands J.R. Hepatocellular carcinoma. Semin Liver Dis 1999, 19:233-311.
10. Imai H., Nakano Y., Kiyosawa K., Tan E.M. Increasing titers and changing specificities of antinuclear antibodies in patients with chronic liver disease who develop hepatocellular carcinoma. Cancer 1993, 71:26-35.
11. Imai H., Furuta K., Landberg G., et al. Autoantibody to DNA isomerase II in primary liver cancer. Clin Cancer Res 1995, 1:417-424.
12. Mihas A.A., Abou-Assi S.G., Heuman D.M. Cutaneous morphea associated with chronic hepatitis C. J Hepatol 2002, 37:412-413.
13. Badri T., El Euch D., Maamouri N., et al. Generalized cutaneous morphea in a patient with post-hepatitis C cirrhosis. Acta Dermatovenerol Alp Panonica Adriat 2007, 16(1):40-41.
14. Abu-Shakra M., Sukenik S., Buskila D. Systemic sclerosis: another rheumatic disease associated with hepatitis C virus infection. Clin Rheumatol 2000, 19(5):378-380.
15. Yamauchi T., Naoe T., Kurosawa Y., Shiku H., Yamada K. Autoantibodies to c-myc nuclear protein products in autoimmune disease. Immunology 1990, 69(1):117-120.
16. Crawford L.V., Pim D.C., Bulbrook R.D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30:403-408.
17. Mimura Y., Yazawa N., Tamaki Z., et al. Anti-p53 antibodies in patients with dermatomyositis/polymyositis. Clin Rheumatol 2007, 26(8):1328-1331. [Epub 2006 Nov 21].
18. Tomkiel J.E., Alansari H., Tang N., et al. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin Cancer Res 2002, 8:752-758.
19. Yamasaki Y., Narain S., Hernandez L., et al. Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. Arthritis Res Ther 2006, 8(4):R111.
20. O'Neill J.H., Murray N.M.F., Newsom-Davis J. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 1988, 111:577-582.
21. Lennon V.A., Lambert E.H., Whittingham S., et al. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982, 5(Suppl. 9):S21-S25.
22. Wirtz P.W., Willcox N., van der Slik A.R. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005, 159:230-237.
23. Maddison P., Newsom-Davis J., Mills K.R., Souhami R.L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999, 353:117-118.
24. Hill C.L., Zhang Y., Sigurgeirsson B., et al. Frequency of specific cancer types in dermatomyositis and plymyositis: a population-based study. Lancet 2001, 357:96-100.
25. Sheil A.G. Cancer after transplantation. World J Surg 1986, 10:389-396.
26. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996, 61:274-278.
27. Fishman P., et al. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 1997, 79:1461-1464.
28. Fishman P., et al. Vitiligo autoantibodies are effective against melanoma. Cancer 1993, 72:2365-2369.
29. Merimsky O. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo). Hum Antibodies Hybridomas 1996, 7:151-156.
30. Nordlund J.J., Kirkwood J.M., Forget B.M., et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 1983, 9:689-696.
31. Duhra P., Ilchyshyn A. Prolonged survival in metastatic malignant melanoma associated with vitiligo. Clin Exp Dermatol 1991, 16:303-305.
32. Hara I., Takechi Y., Houghton A.N. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995, 182(5):1609-1614.
33. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 2002, 188:122-135.
34. Cheever M.A., Disis M.L., Bernhard H., et al. Immunity to oncogenic proteins. Immunol Rev 1995, 145:33-59.
35. Hinchcliffe E.H., Sluder G. 'It Takes Two to Tango': understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev 2001, 15:1167-1181.
36. Fukasawa K., Choi T., Kuriyama R., et al. Abnormal centrosome amplification in the absence of p53. Science 1996, 271(5256):1744-1747.
37. Flory M.R., Moser M.J., Monnat R.J., Davis T.N. Identification of a human centrosomal calmodulin-binding protein that shares homology with pericentrin. Proc Natl Acad Sci USA 2000, 97:5919-5923.
38. Gavanescu I., Vazquez-Abad D., McCauley J., et al. Centrosome proteins: a major class of autoantigens in scleroderma. J Clin Immunol 1999, 19(3):166-171.
39. Mimori T., Akizuki M., Yamagata H., et al. Characterization of a high molecular weight acidic nuclear protein recognized by autoantibodies in sera from patients with polymyositis-scleroderma overlap. J Clin Invest 1981, 68:611-620.
40. Schild-Poulter C., Su A., Shih A., et al. Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. Rheumatology (Oxford) 2008, 47(2):165-171.
41. Fernández-Madrid F., Tang N., Alansari H., et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res 2004, 64(15):5089-5096.
42. Takasaki Y., Deng J.S., Tan E.M. A nuclear antigen associated with cell proliferation and blast transformation. Its distribution in synchronized cells. J Exp Med 1981, 154:1899-1909.
43. Morris G.F., Mathews M.B. Regulation of proliferating cell nuclear antigen during the cell cycle. J Biol Chem 1989, 264:13856-13864.
44. Muro Y., Tsai W.-M., Houghten R., Tan E.M. Synthetic compound peptides simulatingantigenicity of conformation-dependent autoepitopes. J Biol Chem 1994, 269:18529-18534.
45. Shero J.H., Bordwell B., Rothfield N.F., Earnshaw W.C. Autoantibodies to topoisomerase I are found in sera from scleroderma patients. Science 1986, 231:737-740.
46. Agris P.F., Parks R., Bowman L., Guenther R.H., Kovacs S.A., Pelsue S. Plant DNA topoisomerase I is recognized and inhibited by human Scl-70 autoantibodies. Exp Cell Res 1990, 189:276-279.
47. Chen B.M., Chen J.Y., Kao M., et al. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy. Gynecol Oncol 2000, 79(2):272-280.
48. Costenbader K.H., Karlson E.W. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006, 15:737-745.
49. Costenbader K.H., Kim D.J., Peerzada J. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004, 50(3):849-857.
50. Nagataki S., Shibata Y., Inoue S., et al. Thyroid diseases among atomic bomb survivors in Nagasaki. JAMA 1994, 272(5):364-370.
51. Kato H., Duff I.F., Russell W.J., et al. Rheumatoid arthritis and gout in Hiroshima and Nagasaki, Japan. A prevalence and incidence study. J Chronic Dis 1971, 23(9):659-679.
52. Shichikawa K., Inoue K., Hirota S., et al. Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965-1996. Ann Rheum Dis 1999, 58(12):751-756.
53. Cooper G.S., Miller F.W., Germolec D.R. Occupational exposures and autoimmune diseases. Int Immunopharmacol 2002, 2(2-3):303-313.
54. Turner-Warwick M., Parkes W.R. Circulating rheumatoid and antinuclear factors in asbestos workers. Br Med J 1970, 3(5721):492-495.
55. Lambe M., Bjornadal L., Neregard P., et al. Childbearing and the risk of scleroderma: a population-based study in Sweden. Am J Epidemiol 2004, 159:162-166.
56. Costenbader K.H., Feskanich D., Stampfer M.J., Karlson E.W. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007, 56(4):1251-1262.
57. Tan E.M., Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:338-340.
58. Naschitz J.E., Rosner I., Rozenbaum M., et al. Rheumatic syndromes: clues to occult neoplasia. Semin Arthritis Rheum 1999, 29(1):43-55.
59. Stummvoll G.H., Aringer M., Machold K.P., et al. Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasms. Report of two cases and review of the literature. Scand J Rheumatol 2001, 30(1):40-44.
60. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008, 101(1):59-62.
61. Hill C.L., Nguyen A.-M., Rader D., Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62:728-731.
62. Lee P., Alderdice C., Wilkinson S., Keystone E.C., Urowitz M.B., Gladman D.D. Malignancy in progressive systemic sclerosis: association with breast carcinoma. J Rheumatol 1983, 10:665-666.
63. Forbes A.M., Woodrow J.C., Verbov J.L., Graham R.M. Carcinoma of breast and scleroderma: four further cases and a literature review. Br J Rheumatol 1989, 28:65-69.
64. Duncan S.C., Winkelmann R.K. Cancer and scleroderma. Arch Dermatol 1979, 115:950-955.
65. Abu-Shakra M., Guillemin F., Lee P. Cancer in systemic sclerosis. Arthritis Rheum 1993, 36:460-464.
66. Lu T.Y., Hill C.L., Pontifex, E.K., Roberts-Thomson P.J. Breast cancer and systemic sclerosis: a clinical description of 21 patients in a population-based cohort study. Rheumatol Int 2008, 28:895-899.
67. Brenner A.V., Linet M.S., Fine H.A., et al. History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer 2002, 99:252-259.